I-Mab Soars 11.15% on Promising Givastomig Trial Data

On June 26, 2025, I-Mab's stock surged by 11.15% in pre-market trading, reflecting significant investor optimism and market confidence in the company's recent developments.

I-Mab's stock price has been positively influenced by the release of encouraging data from its Phase 1b clinical trial for Givastomig. The trial demonstrated a 71% objective response rate (ORR) per RECIST v1.1, with a favorable safety profile. Notably, an 83% ORR was observed in patients across selected doses, indicating strong efficacy in the treatment of gastric cancers.

Additionally, I-Mab's presentation at the ESMO Gastrointestinal Cancers Congress 2025 further bolstered investor confidence. The company highlighted positive data from the Phase 1b study, which included a combination of Givastomig with immunochemotherapy in patients with first-line gastric cancers. This data underscores the potential of Givastomig as a promising therapeutic option, driving investor enthusiasm and contributing to the stock's upward trajectory.